glp-1 weight loss drug market size 2025 GLP-1 Analogues Market Size, Share & Forecast Report, 2034

Retatrutide 20mg pen

22.83

★★★★☆4.1 (200)

Retatrutide Weight Loss: Results, Timeline & What to Expect

25.72

★★★★★4.2 (206)

Expanded Access (Compassionate Use) Submission Data

23.56

★★★★★4.9 (206)

Retatrutide, a new weight loss drug not available on the market yet, is showing promising results in trials. @DrLaPook explains it's doing much more than what current medications can

23.89

★★★★★4.7 (127)

Compassionate access and emergency use - Research and Innovation

21.48

★★★★★4.5 (280)

White House officials on Tuesday shot down a report speculating that President Trump gained access to the retatrutide weight-loss drug under the Food and Drug Administration's (FDA) “compassionate use program.” Read more:

26.45

★★★★★4.2 (36)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

22.83

★★★★★4.3 (276)